{"gene":"EXOSC9","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2003,"finding":"The N-terminally extended form of PM/Scl-75 (EXOSC9), containing 84 additional amino acids, is required for association with the exosome complex; the shorter previously described isoform fails to interact. The interaction with the exosome is mediated by protein-protein contacts with subunits hRrp46p and hRrp41p, confirmed by mammalian two-hybrid assay.","method":"Co-immunoprecipitation, mammalian two-hybrid system, cDNA cloning and deletion analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal protein interaction assays with deletion mapping and two orthogonal methods (Co-IP + two-hybrid) in a single focused study","pmids":["12788944"],"is_preprint":false},{"year":2003,"finding":"The C-terminal basic region of EXOSC9 contains a nuclear localization signal sufficient (but not essential) for nuclear localization; deletion of this element abrogates nucleolar accumulation of EXOSC9 without disrupting its association with the exosome complex, indicating this element specifically targets the exosome to the nucleolus.","method":"Deletion mutagenesis, subcellular localization by fluorescence microscopy, Co-immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct localization experiment with functional consequence, deletion mutagenesis separating NLS function from exosome association, two orthogonal methods in single rigorous study","pmids":["12788944"],"is_preprint":false},{"year":2007,"finding":"EXOSC9 (PM/Scl-75) is cleaved during apoptosis by caspases; caspase-1 cleaves it most efficiently, caspase-8 to a smaller extent, and caspase-3/7 relatively inefficiently. Cleavage occurs at Asp369 (IILD369G) in the C-terminal region, and at least a fraction of the N-terminal cleavage fragment remains associated with the exosome complex.","method":"In vitro cleavage assay with recombinant caspases, caspase inhibitor treatment, site identification by mutagenesis/mapping, Co-immunoprecipitation of cleavage fragments","journal":"Arthritis research & therapy","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with recombinant caspases, site-specific mapping, confirmed by inhibitor panel; multiple orthogonal methods in a single study","pmids":["17280603"],"is_preprint":false},{"year":2018,"finding":"Disease-causing recessive variants in EXOSC9 (p.Leu14Pro; p.Arg161*) reduce EXOSC9 protein levels in patient fibroblasts and skeletal muscle and disrupt assembly of the entire multi-subunit exosome complex, as shown by blue-native PAGE. Loss of exosc9 in zebrafish (morpholino knockdown and CRISPR/Cas9) causes absence of cerebellum/hindbrain portions and failure of motor neuron development and migration.","method":"Blue-native PAGE, patient cell western blot, zebrafish morpholino knockdown, CRISPR/Cas9 mutagenesis, RNA sequencing","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (BN-PAGE, KO in two model systems, RNA-seq), replicated across multiple patient-derived materials and in vivo model","pmids":["29727687"],"is_preprint":false},{"year":2015,"finding":"Knockdown of exosc9 in Xenopus embryos impairs skin development, producing dorsal blisters characterized by increased apical surface of goblet cells, loss of adhesion between sensorial and peridermal layers, and reduced ciliated cells. This is accompanied by altered expression of epidermal and genodermatosis-related genes, demonstrating a post-transcriptional regulatory role of the RNA exosome in skin integrity.","method":"Morpholino oligonucleotide knockdown in Xenopus, histology, electron microscopy, RNA sequencing","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — loss-of-function with defined cellular phenotype and transcriptomic readout, single study in Xenopus model","pmids":["26546114"],"is_preprint":false},{"year":2020,"finding":"EXOSC9 depletion in cancer cells attenuates P-body formation and stress resistance through its RNA-binding motif; depletion of EXOSC2 or EXOSC4 also reduces P-body number coincident with decreased EXOSC9 protein. The EXOSC9 RNA-binding motif is required for its pro-tumorigenic activity in xenograft models.","method":"siRNA knockdown, P-body quantification by microscopy, RNA-seq, xenograft tumor growth assay, RNA-binding motif mutant rescue","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined cellular phenotype, domain-specific mutant rescue, and in vivo xenograft validation; single lab","pmids":["32518284"],"is_preprint":false},{"year":2023,"finding":"EXOSC9 is recruited to telomeres by SUMO-modified HP1α and degrades lncRNA TERRA in a cell cycle-dependent manner (enriched at S/G2); this activity is required for telomeric integrity, and EXOSC9 knockdown increases telomeric R-loops and DNA damage in endocrine therapy-resistant breast cancer cells.","method":"Co-immunoprecipitation (SUMO-HP1α/EXOSC9 interaction), ChIP/CHIP at telomeres, knockdown with telomeric R-loop and DNA damage readouts, cell cycle analysis","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP for interaction, knockdown with functional readouts, single lab, single study","pmids":["37887339"],"is_preprint":false}],"current_model":"EXOSC9 (PM/Scl-75) is a structural subunit of the RNA exosome complex whose N-terminal extension mediates protein-protein interactions with hRrp46p and hRrp41p for complex assembly, while its C-terminal basic region targets the exosome to the nucleolus; it is cleaved at Asp369 by caspase-1 (and to lesser extents by caspase-8/3/7) during apoptosis, retaining partial exosome association; it is required for correct RNA processing, P-body formation (via its RNA-binding motif), motor neuron development, skin integrity, and telomeric TERRA degradation (through recruitment by SUMO-HP1α), with disease-causing variants disrupting whole-complex exosome assembly and causing pontocerebellar hypoplasia with spinal motor neuronopathy."},"narrative":{"mechanistic_narrative":"EXOSC9 (PM/Scl-75) is a structural subunit of the multi-subunit RNA exosome that drives post-transcriptional RNA processing and degradation across multiple developmental and cellular contexts [PMID:12788944, PMID:29727687]. Its N-terminally extended form, bearing 84 additional residues, is required for incorporation into the exosome through direct protein-protein contacts with the hRrp46p and hRrp41p subunits, whereas a shorter isoform cannot associate [PMID:12788944]. A C-terminal basic region carries a nuclear localization signal that specifically directs the assembled exosome to the nucleolus without being required for complex association [PMID:12788944]. EXOSC9 is required for whole-complex exosome assembly: recessive disease variants reduce EXOSC9 protein and disrupt assembly of the entire exosome, causing loss of cerebellum/hindbrain tissue and failure of motor neuron development and migration in zebrafish, defining EXOSC9 as a cause of pontocerebellar hypoplasia with spinal motor neuronopathy [PMID:29727687]. Beyond core assembly, EXOSC9 supports epidermal integrity and ciliated-cell formation in Xenopus skin [PMID:26546114], promotes P-body formation and stress resistance through its RNA-binding motif [PMID:32518284], and is recruited to telomeres by SUMO-modified HP1α to degrade the lncRNA TERRA in a cell-cycle-dependent manner, limiting telomeric R-loops and DNA damage [PMID:37887339]. During apoptosis EXOSC9 is cleaved at Asp369 most efficiently by caspase-1, with the N-terminal fragment retaining partial exosome association [PMID:17280603].","teleology":[{"year":2003,"claim":"It was unknown how PM/Scl-75 joins the exosome and what governs its localization; mapping the assembly interface and a targeting signal established the protein as a structural exosome subunit with a dedicated nucleolar-targeting element.","evidence":"Co-IP, mammalian two-hybrid, deletion mutagenesis, and fluorescence localization in mammalian cells","pmids":["12788944"],"confidence":"High","gaps":["Atomic structure of the EXOSC9-hRrp46p/hRrp41p interface not resolved","Mechanism by which the NLS recruits nuclear import machinery not defined"]},{"year":2007,"claim":"Whether EXOSC9 is a target of programmed cell death machinery was unknown; identifying caspase-1 cleavage at Asp369 linked the exosome subunit to apoptotic processing.","evidence":"In vitro cleavage with recombinant caspases, inhibitor panel, site mapping, and Co-IP of fragments","pmids":["17280603"],"confidence":"High","gaps":["Functional consequence of cleavage for exosome activity in apoptotic cells not established","Whether cleavage occurs in physiological apoptosis in vivo untested"]},{"year":2015,"claim":"The developmental requirement for the RNA exosome in epithelial tissue was unclear; loss of exosc9 in Xenopus revealed a post-transcriptional role in skin integrity and ciliated-cell formation.","evidence":"Morpholino knockdown in Xenopus with histology, EM, and RNA-seq","pmids":["26546114"],"confidence":"Medium","gaps":["Direct RNA substrates underlying the skin phenotype not identified","Single model organism, no mammalian skin validation"]},{"year":2018,"claim":"The disease relevance of EXOSC9 was unknown; biallelic variants were shown to destabilize the protein, disrupt assembly of the entire exosome, and cause neurodevelopmental defects, establishing EXOSC9 as a cause of pontocerebellar hypoplasia with spinal motor neuronopathy.","evidence":"Blue-native PAGE, patient cell western blot, zebrafish morpholino and CRISPR knockdown, RNA-seq","pmids":["29727687"],"confidence":"High","gaps":["RNA substrates whose mis-processing drives motor neuron loss not defined","Why motor neurons and cerebellum are selectively vulnerable unexplained"]},{"year":2020,"claim":"It was unclear whether EXOSC9 has cytoplasmic RNA-granule functions; depletion studies linked it to P-body formation, stress resistance, and tumor growth via its RNA-binding motif.","evidence":"siRNA knockdown, P-body quantification, RNA-seq, RNA-binding-motif mutant rescue, and xenograft assays","pmids":["32518284"],"confidence":"Medium","gaps":["Mechanism linking exosome activity to P-body assembly not resolved","Single lab; pro-tumorigenic mechanism not generalized across cancer types"]},{"year":2023,"claim":"How the exosome is targeted to telomeres was unknown; EXOSC9 was shown to be recruited by SUMO-HP1α to degrade TERRA and protect telomeric integrity in a cell-cycle-dependent manner.","evidence":"Co-IP, telomeric ChIP, knockdown with R-loop and DNA-damage readouts, cell-cycle analysis in breast cancer cells","pmids":["37887339"],"confidence":"Medium","gaps":["Reciprocal validation of the SUMO-HP1α/EXOSC9 interaction limited","Generality beyond endocrine therapy-resistant breast cancer untested"]},{"year":null,"claim":"The specific RNA substrates whose processing or degradation by EXOSC9 underlies each tissue-specific phenotype (motor neuron, skin, telomere, P-body) remain unidentified, leaving the mechanistic link between exosome activity and these outcomes open.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No direct substrate catalog tied to disease or developmental phenotypes","No structural model of the human exosome containing EXOSC9"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[5,6]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,3]}],"localization":[{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[1]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[0,3]}],"complexes":["RNA exosome"],"partners":["EXOSC6","EXOSC4","EXOSC2","HP1Α"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q06265","full_name":"Exosome complex component RRP45","aliases":["Autoantigen PM/Scl 1","Exosome component 9","P75 polymyositis-scleroderma overlap syndrome-associated autoantigen","Polymyositis/scleroderma autoantigen 1","Polymyositis/scleroderma autoantigen 75 kDa","PM/Scl-75"],"length_aa":439,"mass_kda":48.9,"function":"Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defects, thereby limiting or excluding their export to the cytoplasm. The RNA exosome may be involved in Ig class switch recombination (CSR) and/or Ig variable region somatic hypermutation (SHM) by targeting AICDA deamination activity to transcribed dsDNA substrates. In the cytoplasm, the RNA exosome complex is involved in general mRNA turnover and specifically degrades inherently unstable mRNAs containing AU-rich elements (AREs) within their 3' untranslated regions, and in RNA surveillance pathways, preventing translation of aberrant mRNAs. It seems to be involved in degradation of histone mRNA. The catalytic inactive RNA exosome core complex of 9 subunits (Exo-9) is proposed to play a pivotal role in the binding and presentation of RNA for ribonucleolysis, and to serve as a scaffold for the association with catalytic subunits and accessory proteins or complexes. EXOSC9 binds to ARE-containing RNAs","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q06265/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/EXOSC9","classification":"Common Essential","n_dependent_lines":1093,"n_total_lines":1208,"dependency_fraction":0.9048013245033113},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CAPZB","stoichiometry":0.2},{"gene":"DRG1","stoichiometry":0.2},{"gene":"PSPC1","stoichiometry":0.2},{"gene":"RPS16","stoichiometry":0.2},{"gene":"SRP68","stoichiometry":0.2},{"gene":"SRP9","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/EXOSC9","total_profiled":1310},"omim":[{"mim_id":"618065","title":"PONTOCEREBELLAR HYPOPLASIA, TYPE 1D; PCH1D","url":"https://www.omim.org/entry/618065"},{"mim_id":"607596","title":"PONTOCEREBELLAR HYPOPLASIA, TYPE 1A; PCH1A","url":"https://www.omim.org/entry/607596"},{"mim_id":"606180","title":"EXOSOME COMPONENT 9; EXOSC9","url":"https://www.omim.org/entry/606180"},{"mim_id":"606019","title":"EXOSOME COMPONENT 8; EXOSC8","url":"https://www.omim.org/entry/606019"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoli","reliability":"Enhanced"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/EXOSC9"},"hgnc":{"alias_symbol":["PM/Scl-75","Rrp45p","RRP45","p5","p6"],"prev_symbol":["PMSCL1"]},"alphafold":{"accession":"Q06265","domains":[{"cath_id":"3.30.230.70","chopping":"27-284","consensus_level":"medium","plddt":92.7315,"start":27,"end":284}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q06265","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q06265-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q06265-F1-predicted_aligned_error_v6.png","plddt_mean":77.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=EXOSC9","jax_strain_url":"https://www.jax.org/strain/search?query=EXOSC9"},"sequence":{"accession":"Q06265","fasta_url":"https://rest.uniprot.org/uniprotkb/Q06265.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q06265/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q06265"}},"corpus_meta":[{"pmid":"19220911","id":"PMC_19220911","title":"Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.","date":"2009","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19220911","citation_count":93,"is_preprint":false},{"pmid":"29727687","id":"PMC_29727687","title":"Variants in EXOSC9 Disrupt the RNA Exosome and Result in Cerebellar Atrophy with Spinal Motor Neuronopathy.","date":"2018","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29727687","citation_count":71,"is_preprint":false},{"pmid":"14872500","id":"PMC_14872500","title":"PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome.","date":"2004","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/14872500","citation_count":59,"is_preprint":false},{"pmid":"32518284","id":"PMC_32518284","title":"EXOSC9 depletion attenuates P-body formation, stress resistance, and tumorigenicity of cancer cells.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32518284","citation_count":29,"is_preprint":false},{"pmid":"12788944","id":"PMC_12788944","title":"The association of the human PM/Scl-75 autoantigen with the exosome is dependent on a newly identified N terminus.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12788944","citation_count":24,"is_preprint":false},{"pmid":"33040083","id":"PMC_33040083","title":"Novel EXOSC9 variants cause pontocerebellar hypoplasia type 1D with spinal motor neuronopathy and cerebellar atrophy.","date":"2020","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33040083","citation_count":21,"is_preprint":false},{"pmid":"26546114","id":"PMC_26546114","title":"Ptbp1 and Exosc9 knockdowns trigger skin stability defects through different pathways.","date":"2015","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/26546114","citation_count":17,"is_preprint":false},{"pmid":"30690203","id":"PMC_30690203","title":"Expanded PCH1D phenotype linked to EXOSC9 mutation.","date":"2019","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30690203","citation_count":14,"is_preprint":false},{"pmid":"17280603","id":"PMC_17280603","title":"Caspase-mediated cleavage of the exosome subunit PM/Scl-75 during apoptosis.","date":"2007","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17280603","citation_count":9,"is_preprint":false},{"pmid":"37887339","id":"PMC_37887339","title":"Exosc9 Initiates SUMO-Dependent lncRNA TERRA Degradation to Impact Telomeric Integrity in Endocrine Therapy Insensitive Hormone Receptor-Positive Breast Cancer.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37887339","citation_count":7,"is_preprint":false},{"pmid":"24696107","id":"PMC_24696107","title":"Identification of UACA, EXOSC9, and ΤΜX2 in bovine periosteal cells by mass spectrometry and immunohistochemistry.","date":"2014","source":"Analytical and bioanalytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24696107","citation_count":5,"is_preprint":false},{"pmid":"10708524","id":"PMC_10708524","title":"Structure and localization of mouse Pmscl1 and Pmscl2 genes.","date":"2000","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10708524","citation_count":2,"is_preprint":false},{"pmid":"32238743","id":"PMC_32238743","title":"[A rare case of inclusion body myositis associated with anti-PM/Scl-75 antibodies].","date":"2020","source":"Rinsho shinkeigaku = Clinical neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32238743","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":8549,"output_tokens":1961,"usd":0.027531,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8906,"output_tokens":2691,"usd":0.055903,"stage2_stop_reason":"end_turn"},"total_usd":0.083434,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"The N-terminally extended form of PM/Scl-75 (EXOSC9), containing 84 additional amino acids, is required for association with the exosome complex; the shorter previously described isoform fails to interact. The interaction with the exosome is mediated by protein-protein contacts with subunits hRrp46p and hRrp41p, confirmed by mammalian two-hybrid assay.\",\n      \"method\": \"Co-immunoprecipitation, mammalian two-hybrid system, cDNA cloning and deletion analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal protein interaction assays with deletion mapping and two orthogonal methods (Co-IP + two-hybrid) in a single focused study\",\n      \"pmids\": [\"12788944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The C-terminal basic region of EXOSC9 contains a nuclear localization signal sufficient (but not essential) for nuclear localization; deletion of this element abrogates nucleolar accumulation of EXOSC9 without disrupting its association with the exosome complex, indicating this element specifically targets the exosome to the nucleolus.\",\n      \"method\": \"Deletion mutagenesis, subcellular localization by fluorescence microscopy, Co-immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment with functional consequence, deletion mutagenesis separating NLS function from exosome association, two orthogonal methods in single rigorous study\",\n      \"pmids\": [\"12788944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"EXOSC9 (PM/Scl-75) is cleaved during apoptosis by caspases; caspase-1 cleaves it most efficiently, caspase-8 to a smaller extent, and caspase-3/7 relatively inefficiently. Cleavage occurs at Asp369 (IILD369G) in the C-terminal region, and at least a fraction of the N-terminal cleavage fragment remains associated with the exosome complex.\",\n      \"method\": \"In vitro cleavage assay with recombinant caspases, caspase inhibitor treatment, site identification by mutagenesis/mapping, Co-immunoprecipitation of cleavage fragments\",\n      \"journal\": \"Arthritis research & therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with recombinant caspases, site-specific mapping, confirmed by inhibitor panel; multiple orthogonal methods in a single study\",\n      \"pmids\": [\"17280603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Disease-causing recessive variants in EXOSC9 (p.Leu14Pro; p.Arg161*) reduce EXOSC9 protein levels in patient fibroblasts and skeletal muscle and disrupt assembly of the entire multi-subunit exosome complex, as shown by blue-native PAGE. Loss of exosc9 in zebrafish (morpholino knockdown and CRISPR/Cas9) causes absence of cerebellum/hindbrain portions and failure of motor neuron development and migration.\",\n      \"method\": \"Blue-native PAGE, patient cell western blot, zebrafish morpholino knockdown, CRISPR/Cas9 mutagenesis, RNA sequencing\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (BN-PAGE, KO in two model systems, RNA-seq), replicated across multiple patient-derived materials and in vivo model\",\n      \"pmids\": [\"29727687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Knockdown of exosc9 in Xenopus embryos impairs skin development, producing dorsal blisters characterized by increased apical surface of goblet cells, loss of adhesion between sensorial and peridermal layers, and reduced ciliated cells. This is accompanied by altered expression of epidermal and genodermatosis-related genes, demonstrating a post-transcriptional regulatory role of the RNA exosome in skin integrity.\",\n      \"method\": \"Morpholino oligonucleotide knockdown in Xenopus, histology, electron microscopy, RNA sequencing\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — loss-of-function with defined cellular phenotype and transcriptomic readout, single study in Xenopus model\",\n      \"pmids\": [\"26546114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"EXOSC9 depletion in cancer cells attenuates P-body formation and stress resistance through its RNA-binding motif; depletion of EXOSC2 or EXOSC4 also reduces P-body number coincident with decreased EXOSC9 protein. The EXOSC9 RNA-binding motif is required for its pro-tumorigenic activity in xenograft models.\",\n      \"method\": \"siRNA knockdown, P-body quantification by microscopy, RNA-seq, xenograft tumor growth assay, RNA-binding motif mutant rescue\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined cellular phenotype, domain-specific mutant rescue, and in vivo xenograft validation; single lab\",\n      \"pmids\": [\"32518284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"EXOSC9 is recruited to telomeres by SUMO-modified HP1α and degrades lncRNA TERRA in a cell cycle-dependent manner (enriched at S/G2); this activity is required for telomeric integrity, and EXOSC9 knockdown increases telomeric R-loops and DNA damage in endocrine therapy-resistant breast cancer cells.\",\n      \"method\": \"Co-immunoprecipitation (SUMO-HP1α/EXOSC9 interaction), ChIP/CHIP at telomeres, knockdown with telomeric R-loop and DNA damage readouts, cell cycle analysis\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP for interaction, knockdown with functional readouts, single lab, single study\",\n      \"pmids\": [\"37887339\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"EXOSC9 (PM/Scl-75) is a structural subunit of the RNA exosome complex whose N-terminal extension mediates protein-protein interactions with hRrp46p and hRrp41p for complex assembly, while its C-terminal basic region targets the exosome to the nucleolus; it is cleaved at Asp369 by caspase-1 (and to lesser extents by caspase-8/3/7) during apoptosis, retaining partial exosome association; it is required for correct RNA processing, P-body formation (via its RNA-binding motif), motor neuron development, skin integrity, and telomeric TERRA degradation (through recruitment by SUMO-HP1α), with disease-causing variants disrupting whole-complex exosome assembly and causing pontocerebellar hypoplasia with spinal motor neuronopathy.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"EXOSC9 (PM/Scl-75) is a structural subunit of the multi-subunit RNA exosome that drives post-transcriptional RNA processing and degradation across multiple developmental and cellular contexts [#0, #3]. Its N-terminally extended form, bearing 84 additional residues, is required for incorporation into the exosome through direct protein-protein contacts with the hRrp46p and hRrp41p subunits, whereas a shorter isoform cannot associate [#0]. A C-terminal basic region carries a nuclear localization signal that specifically directs the assembled exosome to the nucleolus without being required for complex association [#1]. EXOSC9 is required for whole-complex exosome assembly: recessive disease variants reduce EXOSC9 protein and disrupt assembly of the entire exosome, causing loss of cerebellum/hindbrain tissue and failure of motor neuron development and migration in zebrafish, defining EXOSC9 as a cause of pontocerebellar hypoplasia with spinal motor neuronopathy [#3]. Beyond core assembly, EXOSC9 supports epidermal integrity and ciliated-cell formation in Xenopus skin [#4], promotes P-body formation and stress resistance through its RNA-binding motif [#5], and is recruited to telomeres by SUMO-modified HP1\\u03b1 to degrade the lncRNA TERRA in a cell-cycle-dependent manner, limiting telomeric R-loops and DNA damage [#6]. During apoptosis EXOSC9 is cleaved at Asp369 most efficiently by caspase-1, with the N-terminal fragment retaining partial exosome association [#2].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"It was unknown how PM/Scl-75 joins the exosome and what governs its localization; mapping the assembly interface and a targeting signal established the protein as a structural exosome subunit with a dedicated nucleolar-targeting element.\",\n      \"evidence\": \"Co-IP, mammalian two-hybrid, deletion mutagenesis, and fluorescence localization in mammalian cells\",\n      \"pmids\": [\n        \"12788944\"\n      ],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Atomic structure of the EXOSC9-hRrp46p/hRrp41p interface not resolved\",\n        \"Mechanism by which the NLS recruits nuclear import machinery not defined\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Whether EXOSC9 is a target of programmed cell death machinery was unknown; identifying caspase-1 cleavage at Asp369 linked the exosome subunit to apoptotic processing.\",\n      \"evidence\": \"In vitro cleavage with recombinant caspases, inhibitor panel, site mapping, and Co-IP of fragments\",\n      \"pmids\": [\n        \"17280603\"\n      ],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Functional consequence of cleavage for exosome activity in apoptotic cells not established\",\n        \"Whether cleavage occurs in physiological apoptosis in vivo untested\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The developmental requirement for the RNA exosome in epithelial tissue was unclear; loss of exosc9 in Xenopus revealed a post-transcriptional role in skin integrity and ciliated-cell formation.\",\n      \"evidence\": \"Morpholino knockdown in Xenopus with histology, EM, and RNA-seq\",\n      \"pmids\": [\n        \"26546114\"\n      ],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct RNA substrates underlying the skin phenotype not identified\",\n        \"Single model organism, no mammalian skin validation\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The disease relevance of EXOSC9 was unknown; biallelic variants were shown to destabilize the protein, disrupt assembly of the entire exosome, and cause neurodevelopmental defects, establishing EXOSC9 as a cause of pontocerebellar hypoplasia with spinal motor neuronopathy.\",\n      \"evidence\": \"Blue-native PAGE, patient cell western blot, zebrafish morpholino and CRISPR knockdown, RNA-seq\",\n      \"pmids\": [\n        \"29727687\"\n      ],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"RNA substrates whose mis-processing drives motor neuron loss not defined\",\n        \"Why motor neurons and cerebellum are selectively vulnerable unexplained\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"It was unclear whether EXOSC9 has cytoplasmic RNA-granule functions; depletion studies linked it to P-body formation, stress resistance, and tumor growth via its RNA-binding motif.\",\n      \"evidence\": \"siRNA knockdown, P-body quantification, RNA-seq, RNA-binding-motif mutant rescue, and xenograft assays\",\n      \"pmids\": [\n        \"32518284\"\n      ],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism linking exosome activity to P-body assembly not resolved\",\n        \"Single lab; pro-tumorigenic mechanism not generalized across cancer types\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"How the exosome is targeted to telomeres was unknown; EXOSC9 was shown to be recruited by SUMO-HP1\\u03b1 to degrade TERRA and protect telomeric integrity in a cell-cycle-dependent manner.\",\n      \"evidence\": \"Co-IP, telomeric ChIP, knockdown with R-loop and DNA-damage readouts, cell-cycle analysis in breast cancer cells\",\n      \"pmids\": [\n        \"37887339\"\n      ],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Reciprocal validation of the SUMO-HP1\\u03b1/EXOSC9 interaction limited\",\n        \"Generality beyond endocrine therapy-resistant breast cancer untested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The specific RNA substrates whose processing or degradation by EXOSC9 underlies each tissue-specific phenotype (motor neuron, skin, telomere, P-body) remain unidentified, leaving the mechanistic link between exosome activity and these outcomes open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No direct substrate catalog tied to disease or developmental phenotypes\",\n        \"No structural model of the human exosome containing EXOSC9\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\n        \"term_id\": \"GO:0003723\",\n        \"supporting_discovery_ids\": [\n          5,\n          6\n        ]\n      },\n      {\n        \"term_id\": \"GO:0005198\",\n        \"supporting_discovery_ids\": [\n          0,\n          3\n        ]\n      }\n    ],\n    \"localization\": [\n      {\n        \"term_id\": \"GO:0005730\",\n        \"supporting_discovery_ids\": [\n          1\n        ]\n      },\n      {\n        \"term_id\": \"GO:0005634\",\n        \"supporting_discovery_ids\": [\n          1\n        ]\n      }\n    ],\n    \"pathway\": [\n      {\n        \"term_id\": \"R-HSA-8953854\",\n        \"supporting_discovery_ids\": [\n          0,\n          3\n        ]\n      }\n    ],\n    \"complexes\": [\n      \"RNA exosome\"\n    ],\n    \"partners\": [\n      \"EXOSC6\",\n      \"EXOSC4\",\n      \"EXOSC2\",\n      \"HP1\\u03b1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}